This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Assays & screens			
Genomics approach for identifying therapeutically vulnerable mutations in non-small cell lung cancer (NSCLC) tumors	<p>An integrated genomics approach applied to NSCLC tumors could be useful for identifying new cancer targets. As proof of concept, the approach showed that KRAS mutations in NSCLC cell lines increased the dependency of cell survival on heat shock protein 90 (Hsp90). As validation of this finding, mice with Kras-driven lung adenocarcinoma that were treated with an Hsp90 inhibitor showed significant tumor regression compared with placebo-treated control mice. According to the researchers, the approach is ready to be used in preclinical drug screening efforts.</p> <p>SciBX 2(21); doi:10.1038/scibx.2009.889 Published online May 28, 2009</p>	Patent applications filed; available for licensing	<p>Sos, M. <i>et al. J. Clin. Invest.</i>; published online May 18, 2009; doi:10.1172/JCI37127</p> <p>Contact: Roman K. Thomas, Max Planck Institute for Neurological Research, Koln, Germany e-mail: nini@nf.mpg.de</p> <p>Contact: Kwok-Kin Wong, Harvard Medical School, Boston, Mass. e-mail: kwong1@partners.org</p> <p>Contact: Matthew Meyerson, same affiliation as above e-mail: matthew_meyerson@dfci.harvard.edu</p>